We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer AG’s (BAYRY - Free Report) third-quarter 2019 core earnings per share of 32 cents per American Depositary Receipt (“ADR”) increased 1.8% year over year. The figure excludes earnings from discontinued operations. Core earnings per ADR also beat the Zacks Consensus Estimate of 29 cents.
Total sales in the quarter were approximately $10.94 billion, up 1.6% from $10.77 billion in the year-ago quarter. The growth was driven by higher sales across segments namely Crop Science, Pharmaceuticals and Consumer Health divisions.
In August, the company entered into an agreement with Elanco to divest its Animal Health business. The company also agreed to sell its 60% stake in Germany-based site services provider, Currenta, to a company controlled by Macquarie Infrastructure and Real Assets in the same month. Bayer reported these two businesses under discontinued operations in the third quarter of 2019.
Shares of the company have risen 3.7% year to date compared with the industry’s increase of 1.6%.
All growth rates mentioned below are on a year-over-year basis, and after adjusting for currency and portfolio changes.
Quarter Highlights
The company started reporting through three segments — Pharmaceuticals, Consumer Health and Crop Science — from the quarter under review.
In the reported quarter, Crop Science sales were €3,948 million, up 4.8% from the year-ago quarter on the back of growth in Latin and North America. Business at this segment has grown well amid challenging market environment. While sales of Fungicides, Corn Seed & Traits and Soybean Seed & Traits were strong during the quarter, segment revenues were hurt by decline in sales of Vegetable Seeds and other.
Please note that lawsuits against the company’s crop protection product, glyphosate, have increased during the quarter driven by higher advertising spend by the plaintiffs. However, the company believes it has meritorious defenses to fight these lawsuits.
Revenues at the Pharmaceuticals segment increased 5.9% to €4,504 million in the third quarter. Growth was backed by consistent strong performance of key products like Xarelto, Eylea, Avalox, Stivarga and Adempas. Strong growth momentum in China continued in this quarter. However, sales of Betaferon/Betaseron, a multiple sclerosis treatment, decreased due to intense competition in the United States. Please note that blood thinner drug, Xarelto, was developed in collaboration with J&J (JNJ - Free Report) , while Regeneron Pharmaceuticals (REGN - Free Report) commercializes eye drug, Eylea, in collaboration with Bayer in ex-U.S. markets.
Consumer Health sales were up 3.7% year over year to €1,288 million in the third quarter. The business gained in Europe/Middle East/Africa ("EMEA") and Latin America on currency and portfolio-adjusted basis. The Pain & Cardio category delivered the strongest performance, with sales increasing 9%. Sales were up in all categories, with Allergy & Cold up 6.4%, except Digestive Health category (down 7.5%).
2019 Guidance
The company updated its view for 2019 to exclude the sales and earnings contributions from Animal Health segment and Currenta. However, expected growth rates remained the same. Sales are expected to be €43.5 billion (previously €46 billion), increasing about 4% on currency and portfolio-adjusted basis.
Core earnings per share are expected to rise to €6.35 (previously €6.80) on a currency-adjusted basis. The guidance takes into account a decline of €0.35 per share due to portfolio measures and €0.10 per share due to currency effects.
Bayer Aktiengesellschaft Price, Consensus and EPS Surprise
Glaxo’s earnings per share estimates have increased from $2.89 to $3.00 for 2019 and from $2.96 to $3.00 for 2020 in the past 60 days.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Rise Y/Y
Bayer AG’s (BAYRY - Free Report) third-quarter 2019 core earnings per share of 32 cents per American Depositary Receipt (“ADR”) increased 1.8% year over year. The figure excludes earnings from discontinued operations. Core earnings per ADR also beat the Zacks Consensus Estimate of 29 cents.
Total sales in the quarter were approximately $10.94 billion, up 1.6% from $10.77 billion in the year-ago quarter. The growth was driven by higher sales across segments namely Crop Science, Pharmaceuticals and Consumer Health divisions.
In August, the company entered into an agreement with Elanco to divest its Animal Health business. The company also agreed to sell its 60% stake in Germany-based site services provider, Currenta, to a company controlled by Macquarie Infrastructure and Real Assets in the same month. Bayer reported these two businesses under discontinued operations in the third quarter of 2019.
Shares of the company have risen 3.7% year to date compared with the industry’s increase of 1.6%.
All growth rates mentioned below are on a year-over-year basis, and after adjusting for currency and portfolio changes.
Quarter Highlights
The company started reporting through three segments — Pharmaceuticals, Consumer Health and Crop Science — from the quarter under review.
In the reported quarter, Crop Science sales were €3,948 million, up 4.8% from the year-ago quarter on the back of growth in Latin and North America. Business at this segment has grown well amid challenging market environment. While sales of Fungicides, Corn Seed & Traits and Soybean Seed & Traits were strong during the quarter, segment revenues were hurt by decline in sales of Vegetable Seeds and other.
Please note that lawsuits against the company’s crop protection product, glyphosate, have increased during the quarter driven by higher advertising spend by the plaintiffs. However, the company believes it has meritorious defenses to fight these lawsuits.
Revenues at the Pharmaceuticals segment increased 5.9% to €4,504 million in the third quarter. Growth was backed by consistent strong performance of key products like Xarelto, Eylea, Avalox, Stivarga and Adempas. Strong growth momentum in China continued in this quarter. However, sales of Betaferon/Betaseron, a multiple sclerosis treatment, decreased due to intense competition in the United States. Please note that blood thinner drug, Xarelto, was developed in collaboration with J&J (JNJ - Free Report) , while Regeneron Pharmaceuticals (REGN - Free Report) commercializes eye drug, Eylea, in collaboration with Bayer in ex-U.S. markets.
Consumer Health sales were up 3.7% year over year to €1,288 million in the third quarter. The business gained in Europe/Middle East/Africa ("EMEA") and Latin America on currency and portfolio-adjusted basis. The Pain & Cardio category delivered the strongest performance, with sales increasing 9%. Sales were up in all categories, with Allergy & Cold up 6.4%, except Digestive Health category (down 7.5%).
2019 Guidance
The company updated its view for 2019 to exclude the sales and earnings contributions from Animal Health segment and Currenta. However, expected growth rates remained the same. Sales are expected to be €43.5 billion (previously €46 billion), increasing about 4% on currency and portfolio-adjusted basis.
Core earnings per share are expected to rise to €6.35 (previously €6.80) on a currency-adjusted basis. The guidance takes into account a decline of €0.35 per share due to portfolio measures and €0.10 per share due to currency effects.
Bayer Aktiengesellschaft Price, Consensus and EPS Surprise
Bayer Aktiengesellschaft price-consensus-eps-surprise-chart | Bayer Aktiengesellschaft Quote
Zacks Rank & Stock to Consider
Bayer currently carries a Zacks Rank #4 (Sell).
GlaxoSmithKline plc (GSK - Free Report) is a better-ranked pharma stock, carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Glaxo’s earnings per share estimates have increased from $2.89 to $3.00 for 2019 and from $2.96 to $3.00 for 2020 in the past 60 days.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>